

CHAPTER VI

REFERENCES

1. Weatherall DJ, *et al.* Pathophysiology of thalassemia. *Clin. Hematol* 1998; 11: 127-46.
2. John SW, David HKC. The α -globin gene cluster: genetics and disorders. *Clin Invest Med* 2001; 24(2): 103-9.
3. Liebhaber SA, Cash FE, Ballas SK. Human α -globin gene expression. The dominant role of the $\alpha 2$ -locus in mRNA and protein synthesis. *J Biol Chem* 1986; 261: 15327-33.
4. Weatherall DJ. *The Thalassemia Syndromes*. Blackwell Scientific: Oxford 1981.
5. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassemias. *Nat Rev Genet* 2001; 2: 245-55.
6. Ponka P, Schulman HM. Regulation of heme biosynthesis: distinct features in erythroid cells. *Stem Cells* 1993; 11(supplement 1): 24-35.
7. Lewin B. *Gene VI*. Oxford University Press, Oxford 1997.
8. Olivieri NF. The β -thalassemias. *N Engl J Med* 1999; 341(2): 99-109.
9. Forget BG. Molecular genetics of the human globin genes. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. *Disorders of hemoglobin; genetics, patho-physiology, and clinical management*. Cambridge [UK]: Cambridge University Press. 2001: 117-30.
10. Higgs DR, Wood WG, Jarman AP, *et al.* A major positive regulatory region located far upstream of the human α -globin gene locus. *Genes Dev* 1990; 4(9): 1588-601.
11. Higgs DR. Molecular mechanisms of α -thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. *Disorders of hemoglobin; genetics, pathophysiology and clinical management*. Cambridge [UK]: Cambridge University Press 2001: 405-30.
12. Gibbons RJ, Higgs DR. The α -thalassemia/mental retardation syndromes. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. *Disorders of hemoglobin; genetics, pathophysiology, and clinical management*. Cambridge [UK]: Cambridge University Press 2001: 470-88.

13. Stamatoyannopoulos G, Grosveld F. Hemoglobin switching. In: Stamatoyannopoulos G, Perlmutter R, Majerus W, Varmus H, eds. *The Molecular Basis of Blood Diseases*. Saunders, Philadelphia 2001: 135-65.
14. Li Q, Harju S, Peterson KR. Locus control regions: coming of age at a decade plus. *Trends Genet* 1999; 15: 403-8.
15. Bulger M, Groudine M. Looping versus linking: toward a model for long distance gene activation. *Genes Dev* 1999; 13: 2465-77.
16. Weatherall DJ, Provan AB. Red cells I: inherited anaemias. *Lancet* 2000; 355 (9210): 1169-75.
17. Giardina P, Hilgartner M. Update on thalassemia. *Pediatr Rev* 1992; 13: 55-62.
18. Weatherall DJ. The thalassemia. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PH, Varmus H, eds. *The molecular basis of blood diseases*. 2nd ed. Philadelphia: Saunder WB. 1994: 157-205.
19. Allen SJ, O'Donnell A, Alexander NDE, *et al.* α^+ -thalassemia protects children against disease caused by other infections as well as malarias. *Proc Natl Acad Sci USA* 1997; 94: 14736-41.
20. Eckman J. Common hemoglobin variants facts. *Genetic Northwest* 1998; 7: 2.
21. Rund D, Rachmilewitz E. Thalassemia major 1995: older patients, new therapies. *Blood Rev* 1995; 9: 25-32.
22. Chernoff AI, Minnich V, Chongchareonsuk S. Hemoglobin E, a hereditary abnormality of human hemoglobin. *Science* 1954; 120: 605-6.
23. Orkin SH, Sexton JP, Cheng TC, *et al.* ATA box transcription mutation in β -thalassemia. *Nucleic Acids Res* 1983; 11: 4727-34.
24. Traeger J, Wood WG, Clegg JB, Weatherall DJ, Wasi P. Defective synthesis of hemoglobin E is due to reduced level of mRNA. *Nature* 1980; 288: 497-9.
25. Fucharoen S, Ketvichit P, Siritanaratkul N, Piankijagum A, Wasi P. Clinical manifestation of β -thalassemia/hemoglobin E disease. *J Pediatr Hematol Oncol* 2000; 22: 552-7.

26. Feng WC, Southwood CM., Bieker JJ. Analyses of β -thalassemia mutant DNA interactions with erythroid kruppel-like factor (EKLF), an erythroid cell-specific transcription factor. *JBC* 1994; 269: 1493-500.
27. Treisman R, Orkin SH, Maniatis T. Specific transcription and RNA splicing defects in five cloned β -thalassemia gene. *Nature* 1983; 302: 591-6.
28. Spritz RA, Jagadeeswaran P, Choudary PV, *et al.* Base substitution in an intervening sequence of a β^+ -thalassemic human globin gene. *PNAS* 1981; 78: 2455-9.
29. Humphries RK, Ley TJ, Anagnou NP, *et al.* β^0 -thalassemia gene: a premature termination codon causes β -mRNA deficiency without affecting cytoplasmic β -mRNA stability. *Blood* 1984; 64: 23-32.
30. Saba L, Meloni A, Sardu R, *et al.* A novel β -thalassemia mutation (G-->A) at the initiation codon of the β -globin gene. *Human Mutation* 1992; 1: 420-2.
31. Winichagoon P, Fucharoen S. Presented at the second Annual Meeting of review of the progress at the nation. In; October 20, 1995; Bangkok, Thailand; October 20, 1995.
32. Laig M, Sanguansermisri T, Wiangnon S, Hundrieser J. The spectrum of β -thalassemia mutation in northern and north eastern Thailand. *Hum Genet* 1989; 87: 45-50.
33. Piomelli S, Loew T. Management of thalassemia major (Cooley's anemia). *Hematol Oncol Clin North Am* 1991; 5: 557-69.
34. Thein SL. Genetic insights into the clinical diversity of thalassaemia. *Br J Haematol* 2004; 124: 264-74.
35. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. *Blood* 1997; 89: 731-61.
36. Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in β -thalassemia intermedia. *Lancet* 1979; 2(8147): 819-21.
37. Risdon RA, Flynn DM, Barry M. The relation between liver iron concentration and liver damage in transfusional iron overload in thalassemia and the effect of chelation therapy. *Gut* 1973; 14 (5): 421.

38. Hershko C, Konijn AM, Link G. Iron chelators for thalassemia. *Br J Haematol* 1998; 101: 399-406.
39. Hershko C, Weatherall DJ. Iron-chelating therapy. *Crit Rev Clin Lab Sci* 1988; 26: 303-45.
40. Douabin V, Moirand R, Jouanolle A, *et al.* Polymorphisms in the HFE Gene. *Hum Here* 1999; 49: 21-6.
41. Feder J, Gnirke A, Thomas W, Tsuchihashi Z. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nature Genetics* 1996; 13: 399-408.
42. Beutler EA, Hoffbrand V, Cook JD. Iron deficiency and overload. *Hematology* 2003: 40-61.
43. Zhou XY, Tomatsu S, Fleming RE, *et al.* HFE gene knockout produces mouse model of hereditary hemochromatosis. *Proc Natl Acad Sci USA* 1998; 95 (5): 2492-7.
44. Nielsen P, Carpinteiro S, Fischer R, Cabeda JM, Porto G, Gabbe EE. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. *Br J Haematol* 1998; 103: 842-5.
45. Gross CN, Irrinki A, Feder JN, Enns CA. Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation. *J. Biol. Chem* 1998; 273: 22068-74.
46. Lebron JA, Bennett MJ, Vaughn DE, *et al.* Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. *Cell* 1998; 93: 111-23.
47. Graham EA, Felgenhauer J, Detter JC, *et al.* Elevated zinc protoporphyrin associated with thalassemia trait and hemoglobin E. *J Pediatr* 1996; 129: 105-110.
48. Hastka J, Lasserre JJ, Schwarzbeck A, *et al.* Laboratory tests of iron status: correlation or common sense? *Clin Chem* 1996; 42: 718-24.
49. Ronin D, Strehl F. Elevation of zinc protoporphyrin levels in lead workers with iron-sufficient microcytosis. *J Occup Environ Med* 1998; 40: 492-6.

50. Celeda A. Iron overload in non-transfused patient with thalassemia intermedia. *Scand J Hematol* 1982; 28 (2): 164-74.
51. Olivieri NF, De SS, Premawardena A, *et al.* Iron overload and iron chelating therapy in hemoglobinE/ β -thalassemia. *J Pediatr Hematol Oncol* 2000; 22 (6): 593-7.
52. Torcharus K, Withayathawornrong W, Sripaisal T, Krutvacho T, Arnutti P, Suwanasophon C. High transfusion in children with β -thalassemia/HbE: clinical and laboratory assessment of 18 cases. *Southeast Asian J Trop Med Public Health* 1993; 24 Suppl 1: 96-9.
53. Siritorn S, Hathirat P, Mahaphan W, *et al.* Iron status of β -thalassemia major. *Thai Journal of Hematol Transfusion Medicine* 1994; 4: 135-8.
54. Pootrakul P, Wattanasaree J, Anuwatanakulchai M, Wasi P. Increased red blood cell protoporphyrin in thalassemia: a result of relative iron deficiency. *Am J Clin Pathol* 1984; 82 (3): 289-93.
55. Tatu T, Udomsappayakul U, Pumala K, Puchaiwattananon O, Hathirat P. The study of zinc protoporphyrin (ZPP) in normal Thai men. *Thai Journal of Hematol Transfusion Medicine* 1996; 6: 112-17.
56. Graham EA, Felgenhauer J, Detter JC, Labbe RF. Elevated zinc protoporphyrin associated with thalassemia trait and hemoglobin E. *J Pediatr* 1996; 129: 105-10.
57. Longo F, Zecchina G, Sbaiz L, Fischer R, Piga A. The influence of hemochromatosis mutations on iron overload of thalassemia major. *Hematologica* 1999; 9: 799-803.
58. Melis MA, Deidda F, Barella S, Cao A, Galanello R. H63D mutation in HFE gene increases iron overload in β -thalassemia carrier. *Hematologica* 2000; 87: 242-5.
59. Rettmer RL. The zinc protoporphyrin/Heme Ratio in Laboratory Diagnosis. *Clin Chem* 1985; 31: 1026.
60. Lewis SM. International Committee for Standardization in Hematology; Propose recommendations for Measurement of Serum Iron in Human Blood. *Am J Clin Pathol* 1971; 56: 543-5.

61. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988; 16: 1215-8.
62. Walsh PS, M.D., Higuchi R. Chelex-100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. *Biotechniques* 1991; 10: 506-13.
63. Sanguanserm Sri T, Phumyu N, Chomchven S, Steger HF. Screening for α -thalassemia-1 heterozygotes in expecting couples by combination of a simple erythrocyte osmotic fragility test and a PCR-based method. *Community Genet* 1999; 2: 26-39.
64. Papanikolaou G, Politou M, Terpos E, Fourlemadis S, Sakellaropoulos N, Loukopoulos D. Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity. *Blood Cells Mol Dis* 2000; 26 (2): 163-8.
65. Gambino SR. In *Standard Method in Clinical Chemistry*. Academic Press 1965; 5:55.
66. Tillyer ML, Tillyer CR. Zinc protoporphyrin assays in patients with α - and β -thalassemia trait. *J clin Pathol* 1994; 47: 205-8.
67. Rees DC, Singh BM, Luo LY, Wickramasinghe S, Thein SL. Nontransfusional iron overload in thalassemia: association with hereditary hemochromatosis. *Ann. NY Acad. Sci* 1998; 850: 490-4.
68. Bothwell TH. Overview and mechanisms of iron regulation. *Nutr Rev* 1995; 53: 237-45.
69. Andrews NC. Disorders of iron metabolism. *N Engl J Med* 1999; 341: 1986-95.
70. Cocuzza S, Avola G. Erythrocyte zincprotoporphyrin (ZPP) in subjects with heterozygote β -thalassemia, acquired non-microcytic anemias and iron deficiency. *Clin Chem* 1994; 40: 768-73
71. Finch C. Regulators of iron balance in human. *Blood* 1994; 84: 800-4.
72. Bottomley SS, Muller-Eberhard U. Pathophysiology of heme. *Semin Hematol* 1988; 25: 182-302.
73. Hastka J, Lasserre JJ, Schwarzbeck A, Strauch M, Hehlmann R. Zinc protoporphyrin in anemia of chronic disorders. *Blood* 1993; 81: 1200-4.

74. Wong SS, Qutishat AS, Lange J, Gornet TG, Buja LM. Detection of iron deficiency anemia in hospitalized patients by zinc protoporphyrin. *Clin Chem Acta* 1996; 244: 91-101.
75. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. *J Med Genet* 1997; 34 (4): 275-8.
76. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. *Genet Test* 2000; 4 (2): 183-98.
77. Pointon JJ, Viprakasit V, Miles KL, *et al.* Hemochromatosis gene (HFE) mutations in South East Asia: a potential for iron overload. *Blood Cells Mol Dis* 2003; 30 (3): 302-6.
78. Chang JG, Liu TC, Lin SF. Rapid diagnosis of the HLA-H gene Cys 282 Tyr mutation in hemochromatosis by polymerase chain reaction--a very rare mutation in the Chinese population. *Blood* 1997; 89 (9): 3492-3.
79. Choi SJ, Min WK, Chun S, *et al.* Frequencies of C282Y and H63D mutations and transferrin saturation indices in the Korean population. *Clin Chem Lab Med* 2002; 40 (7): 689-92.
80. Cullen LM, Gao X, Eastaerl S, Jazwinska EC. The hemochromatosis 845 G-->A and 187 C-->G mutations: prevalence in non-Caucasian populations. *Am J Hum Genet* 1998; 62 (6): 1403-7.
81. Borot N, Roth MP, Malfroy L. Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients. *Immunogenetic* 1997; 45: 320-4.
82. Jazayeri M, Bakayev V, Adibi P, *et al.* Frequency of HFE gene mutations in Iranian β -thalassaemia minor patients. *Eur J Haematol* 2003; 71 (6): 408-11.
83. Viprakasit V, Vathaesathokit P, Chinchang W, *et al.* Prevalence of HFE mutations among the Thai populations and correlation with iron loading in hemoglobin E disorder. *Eur J Haematol* 2004; 73: 43-9.

84. Hastka J, Lasserre JJ, Schwarzbeck A, Strauch M, Hehlmann R. Washing erythrocytes to remove interferences in measurements of zinc protoporphyrin by front-face hematofluorometry. *Clin Chem* 1992; 38: 2184-9.
85. Rettmer RL, Gunter EW, Labbe RF. Overcoming the limitations of hemetofluorometry for assaying zinc protoporphyrin. *Ann NY Acad Sci* 1987; 514: 345-6.
86. Roh YM, Kim K, Kim H. Zinc protoporphyrin IX concentrations between normal adults and the lead-exposed workers measured by HPLC, spectrofluorometer, and hemetofluorometer. *Ind Health* 2000; 38 (4): 372-9.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved